Contact
 

Time Magazine higlights results from the iPrEx study, which found that use of a daily HIV medication reduces HIV infection risk by 43.8 percent.  The magazine sites PrEP as the top medical breakthrough of 2010.  Read more...

The YECI Committee of the Enterprise will be implementing several key initiatives in support of the Scientific Strategic Plan over the next few years.  The Enterprise is looking for motivated, creative and enthusiastic YECIs to join the...

UNAIDS issued a statement calling on all countries to ensure efforts towards universal access to HIV prevention, treatment, care and support are not impeded by bilateral and multilateral trade agreements. The statement says that “in this current...

AVAC announced the selection of their 2011 HIV Prevention Research Advocacy fellows who were selected from a pool of over 60 applicants from 17 countries. Each fellow will receive financial support from AVAC for their 12-month project and fellows...

The Enterprise Board convened via teleconference on 20 October 2010.  Minutes from the meeting are below.

GeoVax is expanding to Phase 2a clinical trial testing of its HIV/AIDS vaccine products.  The expanded Phase 2a trial will test the administration of three doses of the recombinant poxvirus vaccine MVA62B without the use of the recombinant...

The World Health Organization (WHO), UNICEF, the National Institute of Allergy and Infectious Diseases (NIAID) and the Bill & Melinda Gates Foundation have announced a collaboration to increase coordination across the international vaccine...

The GAIA Vaccine Foundation awarded its “International Hope is a Vaccine Award 2010” to Michel Sidibé, Executive Director of UNAIDS, Julie McElrath, Principal Investigator and Director of the HVTN and Gail Skowron, Chief of the Division of...

The AIDS Vaccine 2010 conference welcomed six 10th grade students from the Cesar Chavez Public Charter High School for Public Policy in September.   The students and their...

The Enterprise announced that the Harvard Center for AIDS Research (Harvard CFAR) and the Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University will serve as the Local Host of AIDS...

Global HIV Vaccine Enterprise, 64 Beaver Street, # 352, New York, NY 10004 | +1 212-461-3692 or toll free at +1-866-966-4483
All Content ©2005 - 2013 Global HIV Vaccine Enterprise   |   Terms of Use   |   Privacy Policy   |   Log In / My Account